4.7 Article

PD-L1 induction via the MEK-JNK-AP1 axis by a neddylation inhibitor promotes cancer-associated immunosuppression

期刊

CELL DEATH & DISEASE
卷 13, 期 10, 页码 -

出版社

SPRINGERNATURE
DOI: 10.1038/s41419-022-05292-9

关键词

-

资金

  1. National Key R&D Program of China [2021YFA1101000]
  2. Zhejiang Provincial Natural Science Foundation of China [LD22H300003]

向作者/读者索取更多资源

In this study, it was found that MLN4924 increased the levels of PD-L1 mRNA and protein, which was largely independent of neddylation inactivation. The mechanism involved the activation of ERK and JNK signals, leading to AP-1 activation. MLN4924 attenuated T cell killing and this effect could be abrogated by MEK inhibitor or anti-PD-L1 antibody. Combination of MLN4924 with MEK inhibitor or anti-PD-L1 antibody enhanced the suppression of tumor growth in an in vivo xenograft tumor model.
MLN4924 is a first-in-class small molecule inhibitor of NEDD8-activating enzyme (NAE), which is currently in several clinical trials for anti-cancer applications. However, MLN4924 also showed some off-target effects with potential to promote the growth of cancer cells which counteracts its anticancer activity. In this study, we found that MLN4924 increases the levels of PD-L1 mRNA and protein in dose- and time-dependent manners. Mechanistic study showed that this MLN4924 effect is largely independent of neddylation inactivation, but is due to activation of both ERK and JNK signals, leading to AP-1 activation, which is blocked by the small molecule inhibitors of MEK and JNK, respectively. Biologically, MLN4924 attenuates T cell killing in a co-culture model due to PD-L1 upregulation, which can be, at least in part, abrogated by either MEK inhibitor or anti-PD-L1 antibody. In an in vivo BALB/c mouse xenograft tumor model, while MLN4924 alone had no effect, combination with either MEK inhibitor or anti-PD-L1 antibody enhanced the suppression of tumor growth. Taken together, our study provides a sound rationale for effective anticancer therapy in combination of anti-PD-L1 antibody or MEK inhibitor with MLN4924 to overcome the side-effect of immunosuppression by MLN4924 via PD-L1 induction.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据